Literature DB >> 23436923

Changes in energy metabolism in pheochromocytoma.

O Petrák1, D Haluzíková, P Kaválková, B Štrauch, J Rosa, R Holaj, A Brabcová Vránková, D Michalsky, M Haluzík, T Zelinka, J Widimsky.   

Abstract

CONTEXT: Catecholamine overproduction in pheochromocytoma affects basal metabolism, resulting in weight loss despite normal food intake.
OBJECTIVE: The objective of the study was to evaluate changes in energy metabolism expressed as resting energy expenditure (REE) in patients with pheochromocytoma before and after adrenalectomy and the possible relationship with circulating inflammatory markers.
DESIGN: We measured REE in 17 patients (8 women) with pheochromocytoma by indirect calorimetry (Vmax-Encore 29N system) before and 1 year after adrenalectomy. Body fat percentage was measured with a Bodystat device. Inflammatory markers (leukocytes count and C-reactive protein) and cytokines (TNF-α, IL-6, and IL-8) were analyzed with a Luminex 200.
RESULTS: REE measured in the pheochromocytoma group was 10.4% higher than the predicted value (1731 ± 314 vs 1581 ± 271 kcal/d; P = .004). Adrenalectomy significantly increased body mass index (P =0.004) and the percentage of body fat (P = .01), with a proportional increase in fat distribution (waist circumference, P = .045; hip circumference, P = .001). REE significantly decreased after adrenalectomy (1731 ± 314 vs 1539 ± 215 kcal/d; P = .002), even after adjustments in body surface and body weight (P < .001). After adrenalectomy, we found a significant decrease in leukocyte counts (P = .014) and in the levels of TNF-α (P < .001), IL-6 (P = .048), and IL-8 (P = .007) but not C-reactive protein (P = .09). No significant correlations among calorimetry parameters, hormones, and proinflammatory markers were detected.
CONCLUSIONS: Chronic catecholamine overproduction in pheochromocytoma may lead to a proinflammatory and hypermetabolic state characterized by increased REE. Adrenalectomy leads to the normalization of energy metabolism followed by an increase in body mass index and body fat content and decreases in inflammatory markers and cytokines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23436923     DOI: 10.1210/jc.2012-3625

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Pheochromocytoma presenting as hyperglycemic hyperosmolar syndrome and unusual fever.

Authors:  I-Shuan Lee; Ting-Wei Lee; Chun-Jen Chang; Yu-Mei Chien; Ting-I Lee
Journal:  Intern Emerg Med       Date:  2015-03-03       Impact factor: 3.397

Review 2.  Molecular imaging of brown adipose tissue in health and disease.

Authors:  Matthias Bauwens; Roel Wierts; Bart van Royen; Jan Bucerius; Walter Backes; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-08       Impact factor: 9.236

3.  Unusual case of pheochromocytoma presenting with diabetic ketoacidosis.

Authors:  Yub Raj Sedhai; Kruthika Reddy; Dhruvan Patel; James A Lozada
Journal:  BMJ Case Rep       Date:  2016-10-19

4.  Adrenal medullary dysfunction as a feature of obesity.

Authors:  M Reimann; N Qin; M Gruber; S R Bornstein; C Kirschbaum; T Ziemssen; G Eisenhofer
Journal:  Int J Obes (Lond)       Date:  2017-02-06       Impact factor: 5.095

5.  Dual-Template Magnetic Molecularly Imprinted Polymer for Simultaneous Determination of Spot Urine Metanephrines and 3-Methoxytyramine for the Diagnosis of Pheochromocytomas and Paragangliomas.

Authors:  Hongyu Zeng; Xiaoqing Zhang; Qianna Zhen; Yifan He; Haoran Wang; Yang Zhu; Qi Sun; Min Ding
Journal:  Molecules       Date:  2022-05-30       Impact factor: 4.927

Review 6.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

7.  Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.

Authors:  Akiyuki Kawashima; Masakatsu Sone; Nobuya Inagaki; Kentaro Okamoto; Mika Tsuiki; Shoichiro Izawa; Michio Otsuki; Shintaro Okamura; Takamasa Ichijo; Takuyuki Katabami; Yoshiyu Takeda; Takanobu Yoshimoto; Mitsuhide Naruse; Akiyo Tanabe
Journal:  Endocrine       Date:  2021-07-16       Impact factor: 3.633

8.  Change of skeletal muscle mass in patients with pheochromocytoma.

Authors:  Seung Hun Lee; Mi Kyung Kwak; Seong Hee Ahn; Hyeonmok Kim; Yoon Young Cho; Sunghwan Suh; Kee-Ho Song; Jung-Min Koh; Jae Hyeon Kim; Beom-Jun Kim
Journal:  J Bone Miner Metab       Date:  2018-09-20       Impact factor: 2.626

9.  Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma.

Authors:  Lauren N Krumeich; Andrew J Cucchiara; Katherine L Nathanson; Rachel R Kelz; Lauren Fishbein; Douglas L Fraker; Robert E Roses; Debbie L Cohen; Heather Wachtel
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

10.  Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours.

Authors:  Yaxin An; Manja Reimann; Jimmy Masjkur; Katharina Langton; Mirko Peitzsch; Timo Deutschbein; Martin Fassnacht; Natalie Rogowski-Lehmann; Felix Beuschlein; Stephanie Fliedner; Anthony Stell; Aleksander Prejbisz; Andrzej Januszewicz; Jacques Lenders; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Int J Obes (Lond)       Date:  2018-03-03       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.